Specialized Ophthalmic Formulations for Niche Environments

Publication ID: 24-11857539_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Ophthalmic Formulations for Niche Environments,” Published Technical Disclosure No. 24-11857539_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857539_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,539.

Summary of the Inventive Concept

The inventive concept relates to novel ophthalmic formulations of pilocarpine and brimonidine compounds tailored for specific, narrow market segments or unique operational environments, such as high-altitude, extreme temperatures, disaster relief, high-security, and space exploration.

Background and Problem Solved

The original patent disclosed gel ophthalmic formulations of pilocarpine and brimonidine compounds for treating ophthalmic conditions. However, these formulations may not be suitable for use in specialized environments, such as high-altitude or extreme temperatures, where the efficacy of the formulation may be compromised. The present inventive concept addresses this limitation by providing novel formulations adapted for use in these niche environments.

Detailed Description of the Inventive Concept

The inventive concept comprises a series of specialized ophthalmic formulations of pilocarpine and brimonidine compounds, each tailored for a specific niche environment. For example, a formulation for high-altitude environments may be designed to maintain efficacy at elevations above 10,000 feet, while a formulation for extreme temperatures may be adapted for use in temperatures below -20°C or above 40°C. The formulations may include specific combinations and concentrations of pilocarpine and brimonidine compounds, as well as additional components to enhance stability and efficacy in these environments.

Novelty and Inventive Step

The new claims provide a novel and non-obvious solution by adapting the original formulations for use in specialized environments, which was not contemplated in the original patent. The inventive step lies in the recognition of the need for specialized formulations and the development of specific compositions that address the unique challenges of these environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include formulations adapted for use in other niche environments, such as high-humidity or high-dust environments. Variations of the formulations may also include different concentrations or combinations of pilocarpine and brimonidine compounds, or the inclusion of additional components to enhance efficacy or stability.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the ophthalmic industry, particularly in the areas of high-altitude, extreme temperatures, disaster relief, high-security, and space exploration. The market for these specialized formulations is likely to be niche, but significant, and may include government agencies, military organizations, and private companies operating in these environments.

Field of Art

Pharmaceutical formulations, specifically ophthalmic gel compositions with active pharmaceutical ingredients for treating ocular conditions

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in ophthalmology, having knowledge of drug delivery systems, gel formulation techniques, and experience in adapting pharmaceutical compositions for specialized environments

Obviousness Rationale

A person having ordinary skill in the art would recognize that the source patent's ophthalmic gel composition provides a foundational framework that can be readily adapted to specific environmental conditions. The PTD's variations represent predictable extensions of the original formulation, applying known pharmaceutical engineering principles to modify drug delivery for niche scenarios. The core composition remains substantially similar, with modifications that would be considered routine optimization by a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element
Gel composition with pilocarpine hydrochloride and brimonidine compounds for treating ocular conditions
PTD Variation
Adapting the composition for high-altitude environments by modifying stabilizing agents or concentration ratios
Obviousness Reasoning
A PHOSITA would recognize that environmental factors require routine formulation adjustments to maintain drug efficacy, which involves predictable pharmaceutical engineering techniques
Source Patent Element
Ophthalmic gel with specific concentration ranges of active compounds
PTD Variation
Developing formulations for extreme temperature ranges by adjusting polymer viscosity and thermal stability
Obviousness Reasoning
Modifying gel compositions for temperature resilience is a known technique in pharmaceutical formulation, representing a predictable solution to environmental challenges
Source Patent Element
Pharmaceutically acceptable ophthalmic gel composition
PTD Variation
Creating specialized formulations for disaster relief and high-security environments
Obviousness Reasoning
Tailoring pharmaceutical compositions for specific use cases is a standard practice in drug delivery, involving known techniques of ingredient selection and concentration modification
Source Patent Element
Method of treating ocular conditions using pilocarpine and brimonidine compounds
PTD Variation
Developing a formulation specifically designed for microgravity environments in space exploration
Obviousness Reasoning
Adapting pharmaceutical compositions for unique environmental conditions represents a predictable application of pharmaceutical engineering principles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857539, the variations disclosed herein would be considered obvious to a person having ordinary skill in the art, as they represent predictable modifications of an existing ophthalmic gel composition through routine pharmaceutical engineering techniques. The disclosed variations do not introduce an inventive step beyond the capabilities of an ordinary practitioner in the field of ophthalmic drug formulation.

Original Patent Information

Patent NumberUS 11,857,539
TitleGel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods
Assignee(s)Somerset Therapeutics, LLC